CN115023216A - 抗氧化剂或皮肤应激抑制剂 - Google Patents
抗氧化剂或皮肤应激抑制剂 Download PDFInfo
- Publication number
- CN115023216A CN115023216A CN202180010516.2A CN202180010516A CN115023216A CN 115023216 A CN115023216 A CN 115023216A CN 202180010516 A CN202180010516 A CN 202180010516A CN 115023216 A CN115023216 A CN 115023216A
- Authority
- CN
- China
- Prior art keywords
- skin
- vitamin
- antioxidant
- light
- phycoerythrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 42
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 42
- 239000003112 inhibitor Substances 0.000 title claims abstract description 39
- 239000000126 substance Substances 0.000 claims abstract description 37
- 239000000203 mixture Substances 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 18
- 230000003647 oxidation Effects 0.000 claims abstract description 17
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 17
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 235000006708 antioxidants Nutrition 0.000 claims description 37
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 15
- -1 R-phycocyanin Proteins 0.000 claims description 15
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 13
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 12
- 239000011777 magnesium Substances 0.000 claims description 11
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 10
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 239000002537 cosmetic Substances 0.000 claims description 10
- 229910052749 magnesium Inorganic materials 0.000 claims description 10
- 229960002477 riboflavin Drugs 0.000 claims description 10
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 9
- DLISVLVFJRCVJM-UHFFFAOYSA-N zinc oxygen(2-) phosphane Chemical compound [O--].P.[Zn++] DLISVLVFJRCVJM-UHFFFAOYSA-N 0.000 claims description 9
- 108010053210 Phycocyanin Proteins 0.000 claims description 8
- 229930003471 Vitamin B2 Natural products 0.000 claims description 8
- 235000019164 vitamin B2 Nutrition 0.000 claims description 8
- 239000011716 vitamin B2 Substances 0.000 claims description 8
- 108060006184 phycobiliprotein Proteins 0.000 claims description 7
- CWLKGDAVCFYWJK-UHFFFAOYSA-N 3-aminophenol Chemical compound NC1=CC=CC(O)=C1 CWLKGDAVCFYWJK-UHFFFAOYSA-N 0.000 claims description 6
- FWKJBIILMKHXEI-UHFFFAOYSA-L P.P(=O)(O)([O-])[O-].[Ca+2] Chemical compound P.P(=O)(O)([O-])[O-].[Ca+2] FWKJBIILMKHXEI-UHFFFAOYSA-L 0.000 claims description 6
- 229930003451 Vitamin B1 Natural products 0.000 claims description 6
- 229930003779 Vitamin B12 Natural products 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 6
- 229960003495 thiamine Drugs 0.000 claims description 6
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 6
- 235000010374 vitamin B1 Nutrition 0.000 claims description 6
- 239000011691 vitamin B1 Substances 0.000 claims description 6
- 235000019163 vitamin B12 Nutrition 0.000 claims description 6
- 239000011715 vitamin B12 Substances 0.000 claims description 6
- 235000019158 vitamin B6 Nutrition 0.000 claims description 6
- 239000011726 vitamin B6 Substances 0.000 claims description 6
- 229940011671 vitamin b6 Drugs 0.000 claims description 6
- 108010004469 allophycocyanin Proteins 0.000 claims description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000049 pigment Substances 0.000 claims description 4
- KXXXUIKPSVVSAW-UHFFFAOYSA-K pyranine Chemical compound [Na+].[Na+].[Na+].C1=C2C(O)=CC(S([O-])(=O)=O)=C(C=C3)C2=C2C3=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C2=C1 KXXXUIKPSVVSAW-UHFFFAOYSA-K 0.000 claims description 4
- 229940113490 2,4-diaminophenoxyethanol hydrochloride Drugs 0.000 claims description 3
- PBVFDMZFBPZIMC-UHFFFAOYSA-N 2-(2,4-diaminophenoxy)ethanol;hydrochloride Chemical compound Cl.NC1=CC=C(OCCO)C(N)=C1 PBVFDMZFBPZIMC-UHFFFAOYSA-N 0.000 claims description 3
- GNCOVOVCHIHPHP-UHFFFAOYSA-N 2-[[4-[4-[(1-anilino-1,3-dioxobutan-2-yl)diazenyl]-3-chlorophenyl]-2-chlorophenyl]diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC(C(=C1)Cl)=CC=C1C(C=C1Cl)=CC=C1N=NC(C(C)=O)C(=O)NC1=CC=CC=C1 GNCOVOVCHIHPHP-UHFFFAOYSA-N 0.000 claims description 3
- 229940018563 3-aminophenol Drugs 0.000 claims description 3
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 claims description 3
- 244000178937 Brassica oleracea var. capitata Species 0.000 claims description 3
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 3
- 244000020518 Carthamus tinctorius Species 0.000 claims description 3
- 244000163122 Curcuma domestica Species 0.000 claims description 3
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 3
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 3
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- 235000004347 Perilla Nutrition 0.000 claims description 3
- 244000124853 Perilla frutescens Species 0.000 claims description 3
- 108010004729 Phycoerythrin Proteins 0.000 claims description 3
- 229930003270 Vitamin B Natural products 0.000 claims description 3
- 229930003448 Vitamin K Natural products 0.000 claims description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 3
- 235000013734 beta-carotene Nutrition 0.000 claims description 3
- 239000011648 beta-carotene Substances 0.000 claims description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 3
- 229960002747 betacarotene Drugs 0.000 claims description 3
- 235000021466 carotenoid Nutrition 0.000 claims description 3
- 150000001747 carotenoids Chemical class 0.000 claims description 3
- 235000003373 curcuma longa Nutrition 0.000 claims description 3
- 229930003935 flavonoid Natural products 0.000 claims description 3
- 235000017173 flavonoids Nutrition 0.000 claims description 3
- 150000002215 flavonoids Chemical class 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- 235000012661 lycopene Nutrition 0.000 claims description 3
- 239000001751 lycopene Substances 0.000 claims description 3
- 229960004999 lycopene Drugs 0.000 claims description 3
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 3
- 235000013824 polyphenols Nutrition 0.000 claims description 3
- 150000004032 porphyrins Chemical class 0.000 claims description 3
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 3
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 claims description 3
- 235000013976 turmeric Nutrition 0.000 claims description 3
- 235000019156 vitamin B Nutrition 0.000 claims description 3
- 239000011720 vitamin B Substances 0.000 claims description 3
- 235000019168 vitamin K Nutrition 0.000 claims description 3
- 239000011712 vitamin K Substances 0.000 claims description 3
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 3
- 229940045997 vitamin a Drugs 0.000 claims description 3
- 229940046010 vitamin k Drugs 0.000 claims description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 3
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 claims description 2
- 235000010208 anthocyanin Nutrition 0.000 claims description 2
- 239000004410 anthocyanin Substances 0.000 claims description 2
- 229930002877 anthocyanin Natural products 0.000 claims description 2
- 150000004636 anthocyanins Chemical class 0.000 claims description 2
- 235000012730 carminic acid Nutrition 0.000 claims description 2
- 239000004106 carminic acid Substances 0.000 claims description 2
- 229940080423 cochineal Drugs 0.000 claims description 2
- LQJVOKWHGUAUHK-UHFFFAOYSA-L disodium 5-amino-4-hydroxy-3-phenyldiazenylnaphthalene-2,7-disulfonate Chemical compound [Na+].[Na+].OC1=C2C(N)=CC(S([O-])(=O)=O)=CC2=CC(S([O-])(=O)=O)=C1N=NC1=CC=CC=C1 LQJVOKWHGUAUHK-UHFFFAOYSA-L 0.000 claims description 2
- FPAYXBWMYIMERV-UHFFFAOYSA-L disodium;5-methyl-2-[[4-(4-methyl-2-sulfonatoanilino)-9,10-dioxoanthracen-1-yl]amino]benzenesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC(C)=CC=C1NC(C=1C(=O)C2=CC=CC=C2C(=O)C=11)=CC=C1NC1=CC=C(C)C=C1S([O-])(=O)=O FPAYXBWMYIMERV-UHFFFAOYSA-L 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- ZYIBVBKZZZDFOY-UHFFFAOYSA-N phloxine O Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(Br)=C(O)C(Br)=C1OC1=C(Br)C(O)=C(Br)C=C21 ZYIBVBKZZZDFOY-UHFFFAOYSA-N 0.000 claims description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims 2
- 240000001972 Gardenia jasminoides Species 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 abstract description 85
- 230000000694 effects Effects 0.000 abstract description 15
- 210000004927 skin cell Anatomy 0.000 abstract description 5
- 230000035882 stress Effects 0.000 description 45
- 210000004027 cell Anatomy 0.000 description 31
- 238000002474 experimental method Methods 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 11
- 230000036542 oxidative stress Effects 0.000 description 11
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 6
- 238000002493 microarray Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102100028006 Heme oxygenase 1 Human genes 0.000 description 5
- 101001079623 Homo sapiens Heme oxygenase 1 Proteins 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000003642 reactive oxygen metabolite Substances 0.000 description 5
- 239000011787 zinc oxide Substances 0.000 description 5
- 240000002900 Arthrospira platensis Species 0.000 description 4
- 235000016425 Arthrospira platensis Nutrition 0.000 description 4
- 102100027417 Cytochrome P450 1B1 Human genes 0.000 description 4
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 150000003278 haem Chemical class 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000195493 Cryptophyta Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 101710151717 Stress-related protein Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000001678 irradiating effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229910052684 Cerium Inorganic materials 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 244000111489 Gardenia augusta Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000001748 luminescence spectrum Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108010004335 phycoerythrocyanin Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 229940082787 spirulina Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 102100026789 Aryl hydrocarbon receptor repressor Human genes 0.000 description 1
- 108050004261 Aryl hydrocarbon receptor repressor Proteins 0.000 description 1
- GWZYPXHJIZCRAJ-UHFFFAOYSA-N Biliverdin Natural products CC1=C(C=C)C(=C/C2=NC(=Cc3[nH]c(C=C/4NC(=O)C(=C4C)C=C)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O GWZYPXHJIZCRAJ-UHFFFAOYSA-N 0.000 description 1
- RCNSAJSGRJSBKK-NSQVQWHSSA-N Biliverdin IX Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(\C=C/2C(=C(C)C(=C/C=3C(=C(C=C)C(=O)N=3)C)/N\2)CCC(O)=O)N1 RCNSAJSGRJSBKK-NSQVQWHSSA-N 0.000 description 1
- 101100497948 Caenorhabditis elegans cyn-1 gene Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108010077090 Cytochrome P-450 CYP1B1 Proteins 0.000 description 1
- 102000009902 Cytochrome P-450 CYP1B1 Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010018924 Heme Oxygenase-1 Proteins 0.000 description 1
- 102000002737 Heme Oxygenase-1 Human genes 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 241000206618 Porphyridium Species 0.000 description 1
- 241001494715 Porphyridium purpureum Species 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101100451295 Takifugu rubripes hmox gene Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 239000005083 Zinc sulfide Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- QBUVFDKTZJNUPP-UHFFFAOYSA-N biliverdin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(C=C3C(=C(C=C)C(=O)N3)C)=N2)CCC(O)=O)N1 QBUVFDKTZJNUPP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000012745 brilliant blue FCF Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- DGQLVPJVXFOQEV-JNVSTXMASA-N carminic acid Chemical compound OC1=C2C(=O)C=3C(C)=C(C(O)=O)C(O)=CC=3C(=O)C2=C(O)C(O)=C1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DGQLVPJVXFOQEV-JNVSTXMASA-N 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- OOYIOIOOWUGAHD-UHFFFAOYSA-L disodium;2',4',5',7'-tetrabromo-4,5,6,7-tetrachloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(Br)=C([O-])C(Br)=C1OC1=C(Br)C([O-])=C(Br)C=C21 OOYIOIOOWUGAHD-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 125000004387 flavanoid group Chemical group 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 150000002259 gallium compounds Chemical class 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008789 oxidative DNA damage Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000004763 sulfides Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 230000022814 xenobiotic metabolic process Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229910052984 zinc sulfide Inorganic materials 0.000 description 1
- DRDVZXDWVBGGMH-UHFFFAOYSA-N zinc;sulfide Chemical compound [S-2].[Zn+2] DRDVZXDWVBGGMH-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/29—Titanium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0661—Radiation therapy using light characterised by the wavelength of light used ultraviolet
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Biochemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
Abstract
本发明的目的是提供新的抗氧化剂或皮肤应激抑制剂。提供含有波长转换物质作为有效成分的抗氧化剂或皮肤应激抑制剂、含有这样的抗氧化剂或皮肤应激抑制剂的组合物和制品、以及用于在使用了它们的皮肤中抑制氧化和/或皮肤应激的方法。通过本发明,有效地利用紫外线而在皮肤细胞中抑制氧化和/或皮肤应激,从而可以对皮肤发挥有利的作用。
Description
技术领域
本发明涉及含有波长转换物质的抗氧化剂或皮肤应激抑制剂、含有这样的抗氧化剂或皮肤应激抑制剂的组合物和制品、以及用于在使用了它们的皮肤中抑制氧化和/或皮肤应激的方法。
背景技术
作为由紫外线引起的对皮肤的有害影响,例如,有皮肤癌、光老化、斑、皱纹、炎症这样的不良影响,从健康、美容的观点考虑也是不优选的。
因此,采取了大量用于对肌肤防御紫外线的对策。可举出例如,防晒剂的使用、在不接触日光那样的室内的活动、进行了抗UV加工的帽子、衣服、抗紫外线膜的使用等。
现有技术文献
专利文献
专利文献1:日本专利第6424656号公报
专利文献2:日本专利第6361416号公报
专利文献3:国际公开第2018/004006号
专利文献4:日本特开2018-131422号公报
专利文献5:日本特开平5-117127号公报
专利文献6:日本专利第4048420号公报
专利文献7:日本专利第4677250号公报
专利文献8:日本专利第3303942号公报
专利文献9:日本特开2017-88719号公报
专利文献10:国际公开第2018/117117号
发明内容
发明所要解决的课题
本发明的课题是提供利用了紫外线的波长的调制的新的抗氧化剂或皮肤应激抑制剂。
用于解决课题的手段
本发明人等为了能够对皮肤有用地利用紫外线而进行了深入研究。其结果发现,如果紫外线经由转换紫外线的波长的波长转换物质而照射到皮肤细胞,则氧化应激相关蛋白质的表达变化,想到了含有波长转换物质的抗氧化剂或皮肤应激抑制剂。
本申请提供以下发明。
(1)一种抗氧化剂或皮肤应激抑制剂,其含有波长转换物质作为有效成分,
上述波长转换物质转换入射光所包含的紫外线的波长而放出与上述紫外线的波长相比长的波长的出射光。
(2)根据(1)所述的抗氧化剂或皮肤应激抑制剂,上述紫外线在200nm~400nm具有峰波长。
(3)根据(1)或(2)所述的抗氧化剂或皮肤应激抑制剂,上述出射光在450nm~700nm具有峰波长。
(4)根据(1)~(3)中任一项所述的抗氧化剂或皮肤应激抑制剂,上述波长转换物质包含选自别藻蓝蛋白、C-藻蓝蛋白、R-藻蓝蛋白、藻红蓝蛋白、B-藻红蛋白、b-藻红蛋白、C-藻红蛋白、和R-藻红蛋白中的1种或多种藻胆蛋白;选自氧化锌荧光体、钛酸镁荧光体、和磷酸钙荧光体中的1种或多种无机荧光体;选自维生素A、β胡萝卜素、维生素K、维生素B1、维生素B2、维生素B6、维生素B12、叶酸、烟酸、番茄红素、栀子(クチナシ)、红花(ベニバナ)、姜黄(ウコン)、胭脂虫红(コチニール)、紫苏(シソ)、紫甘蓝(赤キャベツ)、黄酮类(flavonoid)、类胡萝卜素、醌型化合物(quinoid)、卟啉类、花色素苷类、和多酚类中的1种或多种成分;以及/或选自红色401号、红色227号、红色504号、红色218号、橙色205号P、黄色4号、黄色5号、绿色201号、绿色204号(Pyranine Conc)、蓝色1号、2,4-二氨基苯氧基乙醇盐酸盐、紫色201号(Alizurine Purple SS)、紫色401号、黑色401号、红色226号(HelindonePink)、黄色401号、黄色205号、蓝色404号、红色104号、和间氨基苯酚中的1种或多种色素。
(5)根据(4)所述的抗氧化剂或皮肤应激抑制剂,上述波长转换物质包含选自别藻蓝蛋白、C-藻蓝蛋白、R-藻蓝蛋白、藻红蓝蛋白、B-藻红蛋白、b-藻红蛋白、C-藻红蛋白、和R-藻红蛋白中的1种或多种藻胆蛋白;选自氧化锌荧光体、钛酸镁荧光体、和磷酸钙荧光体中的1种或多种无机荧光体;以及/或选自维生素B1、维生素B2、维生素B6、和维生素B12中的1种或多种维生素B。
(6)一种组合物,其含有(1)~(5)中任一项所述的抗氧化剂或皮肤应激抑制剂。
(7)根据(6)所述的组合物,上述组合物为皮肤外用组合物,其用于通过使皮肤暴露于包含紫外线的光而在皮肤中的氧化和/或皮肤应激的抑制。
(8)一种用于在对象的皮肤中抑制氧化和/或皮肤应激的美容方法,其包含:
将(6)或(7)所述的组合物涂抹于对象的皮肤;以及
使涂抹上述组合物后的皮肤暴露于包含紫外线的光。
(9)一种制品,其含有(1)~(5)中任一项所述的抗氧化剂或皮肤应激抑制剂。
(10)根据(9)所述的制品,上述制品用于通过使皮肤暴露于使包含紫外线的光通过了该制品后的光从而在皮肤中抑制氧化和/或皮肤应激。
(11)一种用于在对象的皮肤中抑制氧化和/或皮肤应激的美容方法,其包含:
使包含紫外线的光通过(9)或(10)所述的制品;以及
使对象的皮肤暴露于上述通过光。
发明的效果
本发明可以有效地利用紫外线而在皮肤细胞中抑制氧化和/或皮肤应激。基于由此对皮肤带来有利的作用这样的认识。此外,本发明对以往主要作为色素、颜料、紫外线散射剂、紫外线吸收剂、营养成分、抗氧化剂等而被利用的上述化合物提供新的用途。进一步,关于本发明,即使是迄今为止因为美容、健康上的理由而尽量避免了紫外线的人,有时也带来感觉想要积极地外出这样的生活品质的提高。
附图说明
图1为实验1的示意图。
具体实施方式
本发明的抗氧化剂或皮肤应激抑制剂含有波长转换物质作为有效成分。所谓波长转换物质,是指转换入射光所包含的紫外线的波长而放出与上述紫外线的波长相比长的波长的出射光的物质。
紫外线可以包含UVA、UVB、UVC等。在某实施方式中,紫外线为在200nm~400nm具有峰的波长的光。此外,例如在太阳光这样的入射光中可以包含紫外线。或者,入射光可以为紫外线,也可以使用人工生成的紫外线。紫外线能够对皮肤带来各种作用。作为一例,已知紫外线引起晒斑、晒黑这样的晒伤、引起活性氧的生成、对细胞造成DNA的损伤。
通过波长转换物质而放出的出射光与紫外线相比波长长,优选在500nm~700nm具有峰波长。出射光例如虽然没有限定,但是可以在450nm、460nm、470nm、480nm、490nm、500nm、510nm、520nm、530nm、540nm、550nm、560nm、570nm、580nm、590nm、600nm、610nm、620nm、630nm、640nm、650nm、660nm、670nm、680nm、690nm、700nm、或这些数值的任意的范围内具有1或多个峰,或可以为红色光、橙色光、绿色光、蓝色光等。在某实施方式中,波长转换物质在用200nm~400nm的激发光进行了激发时发出的光的主波长显示450nm~700nm,作为一例显示500nm~700nm。
作为波长转换物质的例子,可举出以下成分:可举出别藻蓝蛋白、C-藻蓝蛋白、R-藻蓝蛋白、藻红蓝蛋白、B-藻红蛋白、b-藻红蛋白、C-藻红蛋白、R-藻红蛋白等藻胆蛋白;维生素A、β胡萝卜素、维生素K、维生素B1、维生素B2、维生素B6、维生素B12、叶酸、烟酸、番茄红素、栀子、红花、姜黄、胭脂虫红、紫苏、紫甘蓝、黄酮类、类胡萝卜素、醌型化合物、卟啉类、花色素苷类、多酚类等天然来源或合成成分;红色401号、红色227号、红色504号、红色218号、橙色205号P、黄色4号、黄色5号、绿色201号、绿色204号、蓝色1号、2,4-二氨基苯氧基乙醇盐酸盐、紫色201号、紫色401号、黑色401号、红色226号、黄色401号、黄色205号、蓝色404号、红色104号、间氨基苯酚等色素;掺杂在无机化合物中使其具有荧光的荧光体,例如,日本专利第6424656号所记载的包含非晶质二氧化硅粒子、铈、和磷和/或镁的蓝色荧光体和日本专利第6361416号所记载的包含对碱土金属硫化物与镓化合物的混晶物进行铕活化而得的化合物的红色荧光体、国际公开第2018/004006号所记载的氧化锌荧光体、日本特开2018-131422号所记载的氧化锌荧光体;日本特开平5-117127号所记载的无机荧光体;等。在某实施方式中,无机荧光体为选自下述荧光体中的1种或多种荧光体,所述荧光体为:将可以如ZnO:Zn、Zn1+z、ZnO1-x那样表示的氧化锌用国际公开第2018/004006号所记载的例如硫化锌、硫酸锌等硫化盐和/或硫酸盐这样的含硫化合物掺杂而得的荧光体、将MgTiO3、Mg2TiO4这样的钛酸镁用锰掺杂而得的钛酸镁荧光体、和将Ca(H2PO4)2、CaHPO4、Ca3(PO4)2这样的磷酸钙用铈掺杂而得的磷酸钙荧光体。
波长转换物质可以从动物、植物、藻类等天然物通过提取等方法来获得,也可以通过化学合成这样的人工方法来获得。例如,藻胆蛋白可以通过将螺旋藻(Spirulinaplatensis)等蓝藻类、紫球藻(Porphyridium purpureum)等红藻类这样的藻类通过例如日本专利第4048420号、日本专利第4677250号、日本专利第3303942号等所记载的方法进行提取来调制。氧化锌荧光体可以通过例如国际公开第2018/004006号、日本特开2018-131422号、日本特开平5-117127号所记载的方法来制造。钛酸镁荧光体可以通过日本特开2017-88719号所记载的方法来制造。磷酸钙荧光体可以通过国际公开第2018/117117号所记载的方法来制造。
只要不损害本发明的波长转换效果,这些波长转换物质就可以由上面例示的成分构成,也可以包含上面例示的成分,可以单独使用也可以混合多种。例如,可以在上述藻胆蛋白、无机物荧光体中混合其它波长转换物质例如维生素B(维生素B1、维生素B2、维生素B6、维生素B12等)而以协同效果作为目标。然而,这些成分为例示,也可以使用发挥本发明的波长转换效果的任何物质。
此外,只要不损害本发明的波长转换效果,本发明的抗氧化剂或皮肤应激抑制剂、组合物或制品中的波长转换物质的含量就没有特别限定,可以根据波长转换物质的种类、抗氧化剂或皮肤应激抑制剂或组合物的用途来适当确定。例如,在0.01~99.99重量%、0.1%~999重量%等范围内是任意的。
所谓皮肤应激,是指皮肤、特别是表皮和真皮中的细胞受到的氧化应激。通常,皮肤的细胞通过活性氧(ROS)而受到损伤,引起炎症、皮肤屏障功能的降低。因此,所谓皮肤应激高的状态,是指通过活性氧而皮肤细胞蓄积了损伤的状态。活性氧通过细胞的电子传递系统的异常反应、紫外线照射而产生。如果向本发明的抗氧化剂或皮肤应激抑制剂照射紫外线则产生出射光,出射光通过使皮肤细胞中氧化应激相关蛋白质的表达变化,从而发挥抗氧化作用和/或皮肤应激抑制作用。作为氧化应激相关蛋白质,可举出AhR、AhRR、CYP1B1、和HMOX1等。抗氧化作用和/或皮肤应激抑制作用可以为通过紫外线而被诱发了的氧化应激和/或皮肤应激的抑制作用,也可以为因紫外线以外的原因而被诱发了的氧化应激和/或皮肤应激的抑制作用。本发明的抗氧化剂或皮肤应激抑制剂可以使用于任意的对象,也可以被应用于在室外等被暴露于紫外线的对象、受到氧化应激和/或皮肤应激的对象。
芳香族烃受体(AhR)为属于bHLH-PAS(Basic Helix-Loop-Helix-Per-Arnt-Sim)家族的转录因子。AhR也已知二恶英(Dioxin)等芳香族烃成为配体,被活化而移动到核内,作为转录因子起作用,另一方面,通过UV被活化。通过被活化,从而使作为药物代谢酶的CYP1、谷胱甘肽S-转移酶-Y亚单位等与异生代谢有关的酶组的表达增加,并且将与ROS蓄积有关的途径活化。通过ROS蓄积,从而发生氧化应激,产生炎症细胞因子,并且发生氧化的DNA损伤。
芳香族烃受体阻遏物(AHRR)作为抑制AhR的作用的阻遏物起作用。通过AHRR的表达增大从而AhR的活性被抑制,由此,药物代谢途径和ROS蓄积途径被抑制。
细胞色素P4501B1(CYP1B1)为属于细胞色素P450超家族的酶,是与多环芳香族烃等的药物代谢有关的酶。通过UV照射而在角质形成细胞中表达增大。此外,通过AHR被活化,诱导氧化应激途径。
血红素加氧酶1(HMOX1)为参与血红素代谢的起动步骤的酶。HMOX1将血红素分解为胆绿素。血红素为生命活动所必需的辅基,但从蛋白质游离了的血红素成为产生活性氧的有害的分子。因此,HMOX1的活化有助于氧化应激的降低和抗炎症。HOMX1通过UV照射等的氧化应激而被诱导。
本发明的抗氧化剂或皮肤应激抑制剂和组合物的施与形态是任意的,但为了通过使皮肤暴露于包含紫外线的光而皮肤中的氧化和/或皮肤应激的抑制,有时优选为药品、准药品、化妆品等皮肤外用剂。在使用本发明的抗氧化剂或皮肤应激抑制剂或组合物作为皮肤外用剂的情况下,剂型、涂抹法、施与次数等可以任意确定。例如,可以以化妆水、喷雾、油、霜、乳液、凝胶、防晒剂、晒黑剂这样的形态,定期或不定期地例如早晨、白天、傍晚等1天1次~数次,在外出、野外活动、海洋运动、滑雪等予想暴露于阳光之前等每次涂抹于皮肤。
此外,本发明的抗氧化剂或皮肤应激抑制剂和组合物可以根据需要任意选择例如赋形剂、保存剂、增稠剂、粘合剂、崩解剂、分散剂、稳定剂、胶凝剂、抗氧化剂、表面活性剂、保存剂、油分、粉末、水、醇类、增稠剂、螯合剂、有机硅类、抗氧化剂、保湿剂、香料、各种药效成分、防腐剂、pH调节剂、中和剂等添加剂而并用。进一步,为了提高本发明的效果,也可以并用其它抗氧化剂或皮肤应激抑制剂等。
此外,本发明也提供包含本发明的抗氧化剂或皮肤应激抑制剂的、用于抑制皮肤中氧化和/或皮肤应激的例如遮阳板、帽子、衣服、手套、屏幕膜、窗用喷雾、窗用霜、窗材料、墙壁材料这样的制品。与上述同样地,本发明的制品中的添加剂等的使用、制品的形态等也是任意的。
此外,本发明也提供本发明的抗氧化剂或皮肤应激抑制剂、组合物或制品的制造方法。此外,也提供用于在对象的皮肤中抑制氧化和/或皮肤应激的方法,这里,该方法包含:将本发明的抗氧化剂或皮肤应激抑制剂或组合物涂抹于对象的皮肤、以及使涂抹上述抗氧化剂或皮肤应激抑制剂或组合物后的皮肤暴露于包含紫外线的光;或使包含紫外线的光通过本发明的制品、以及使对象的皮肤暴露于上述通过光,该抗氧化剂或皮肤应激抑制剂、组合物和制品转换入射光所包含的紫外线的波长而放出与上述紫外线的波长相比长的波长的出射光,优选使在200nm~400nm具有峰波长的紫外线通过而成为在450nm~700nm、作为一例在500nm~700nm具有峰波长的光。用于在对象的皮肤中抑制氧化和/或皮肤应激的方法有时以美容作为目的,而不是医生、医疗从业者使用的治疗方法。此外,本发明也提供包含向对象提示本发明的美容方法、抗氧化剂或皮肤应激抑制剂、组合物或制品的、支援对象的美容行为的美容咨询方法。
实施例
接下来通过实施例进一步详细地说明本发明。需要说明的是,本发明不限定于此。
实验1:由各种波长转换物质的应用引起的基因表达的变化
实验1-1:波长转换物质的调制
如以下那样调制出波长转换物质。
(1)C-藻蓝蛋白
C-藻蓝蛋白(C-phycocyanin:Lina Blue)由螺旋藻(Spirulina platensis)提取物获得,吸收光谱在350nm具有峰波长,发光光谱在640nm和700nm具有峰波长。
(2)核黄素(维生素B2)
核黄素(Riboflavin)也被称为维生素B2,吸收光谱在445nm具有峰波长,发光光谱在530nm具有峰波长。
(3)氧化锌荧光体
使用了堺化学工业株式会社制的Lumate G。Lumate G为如国际公开第2018/004006号所记载地那样将ZnO用含硫化合物掺杂后进行烧成而得的氧化锌荧光体,吸收光谱在365nm具有峰波长,发光光谱在510nm具有峰波长。
(4)钛酸镁荧光体
使用了堺化学工业株式会社制的Lumate R。Lumate R为将MgTiO3用锰进行掺杂而得的钛酸镁荧光体,吸收光谱在365nm具有峰波长,发光光谱在660~680nm的带具有峰波长。
将(1)~(2)的波长转换物质溶解于水,调制出1%和5%的浓度的溶液。
(3)~(4)的波长转换物质分散于醇而调制出5%和10%的分散液。
实验1-2:细胞试样的调制
如以下那样调制出细胞试样。
1.使用了Normal Human Epidermal Keratinocytes PromoCell社制的人皮肤角质形成细胞。将用液氮保存了的细胞悬浮液(1mL)供于热水浴(37℃)而解冻为小的冰颗粒残留的程度,接着用9mL的温KGM培养基进行了稀释。
2.将稀释物温和混合后转移到T75烧瓶中,在37℃下孵育了一晚。
3.第二天,将培养基更换为10mL的新鲜培养基。
4.将培养基定期地(2~3天)更换,继续进行细胞的增殖。其间,使用显微镜观察细胞,确认了细胞以正确的形态增殖。
5.在细胞达到约80%的汇合(confluent)后,将细胞传代。
6.细胞的传代通过用10mL的温PBS将细胞洗涤1次后吸引来进行。
7.将5mL的温胰蛋白酶加入到T75烧瓶中,用胰蛋白酶溶液覆盖烧瓶的底面在室温下放置1分钟后吸引。
8.对于角质形成细胞,将烧瓶在37℃的烘箱内静置(最大)5分钟。使用显微镜观察细胞,确认到细胞小且为椭圆形。
9.然后,轻轻地敲击T75烧瓶的侧面而使细胞游离。使用显微镜观察细胞,确认到细胞自由活动。
10.对于角质形成细胞,再悬浮于5mL的温胰蛋白酶中和溶液,转移到灭菌50mLFalcon管。将烧瓶进一步用5mL的温FGM冲洗而加入到Falcon管从而确实地移动全部细胞。
11.将细胞以10,000rpm离心5分钟(4℃),一边注意不打乱细胞颗粒一边除去了上清液。
12.角质形成细胞以4×104细胞/孔(500μL)的浓度再悬浮于KGM,接种于胶原被膜玻璃底4孔室载玻片。
13.将培养基每2~3天更换,使细胞增殖直到达到60~70%的汇合(根据实验的种类而不同)为止。
14.在照射的24小时前,变更为不添加补充剂的培养基。
实验1-3:紫外线的照射
1.在照射的至少30分钟前接通太阳模拟器的电源而使灯变热。太阳模拟器为使用UG11滤光片的设定。UG11滤光片为仅使UVB通过而截止其它波长光的滤光片。通过了UG11滤光片的UV光在300nm~385nm具有峰波长。
2.将温度控制板接通而设定为33℃。
3.将在实验1-2中调制的细胞用温PBS洗涤1次。
4.在各孔中加入0.5mL的加温了的Martinez溶液(145mM NaCl,5.5mM KCl,1.2mMMgCl2.6H2O,1.2mM NaH2PO4.2H2O,7.5mM HEPES,1mM CaCl2,10mM D-葡萄糖)。
5.如图1所示那样,将细胞孔载置在板上,进一步在其上,将在实验1-1中调制的包含波长转换物质(1)~(4)的溶液0.4ml注入到24孔板的各孔中,以覆盖加有细胞的孔的方式载置,波长转换物质的溶液不与细胞溶液直接接触,UV光通过波长转换物质的溶液而被照射到细胞溶液
6.以合计成为100mJ/cm2的剂量的方式进行了照射。此外,作为对照,制作出在细胞孔上不载置波长转换物质的板而向细胞直接照射了UV光的试样、和不向细胞照射UV光而在暗处进行了培养的试样。
7.照射后,将Martinez溶液与加温了的KGM(不添加补充剂)更换,将板返回到37℃的培养箱,孵育了24小时。
实验2:微阵列
实验2-1:RNA提取
将在实验1-3中照射紫外线后孵育了24小时的细胞试样用500μl的温PBS洗涤,将PBS完全吸引。按照制品说明书使用Qiagen RNeasy Mini Kit prep(Qiagen,74106)而提取了RNA。
实验2-2:微阵列
使用Human基因表达用微阵列SurePrint G3 Human GE Microarray 8x60KVer.3.0(Agilent technology),进行了在实验2-1中提取出的RNA的解析。按照AgilentTechnology社提供的规程进行关于提取出的RNA的标记反应、扩增反应、精制、cRNA的定量而调制出杂交样品。将微阵列用AGILINT C MICROARRAY SCANNER观察,特定出通过波长转换物质的有无而表达显著降低或增加了的基因而示于以下。
[表1]
基因名 | Lina Blue | 维生素B2 | Lumate G | Lumate R |
AhR | ○ | ○ | × | ○ |
CYP1B1 | ○ | ○ | × | ○ |
AHRR | ○ | ○ | × | ○ |
HMOX1 | ○ | × | ○ | × |
○是指表达量显著变化了的基因,×是指未见表达量的变化的基因。AhR和CYP1B1的表达降低,AHRR和HMOX1的表达增加了。
根据这些结果,通过对波长转换物质照射UV,从而显示出氧化和/或皮肤应激相关蛋白质的基因表达变化。由此,发挥抑制氧化和/或皮肤应激的效果。
以上,对本发明的实施方式进行了说明。然而,本发明不限定于它们,化妆料、药品组合物等,能够在不超出发明的宗旨的范围适当变更。
Claims (11)
1.一种抗氧化剂或皮肤应激抑制剂,其含有波长转换物质作为有效成分,
所述波长转换物质转换入射光所包含的紫外线的波长而放出与所述紫外线的波长相比长的波长的出射光。
2.根据权利要求1所述的抗氧化剂或皮肤应激抑制剂,所述紫外线在200nm~400nm具有峰波长。
3.根据权利要求1或2所述的抗氧化剂或皮肤应激抑制剂,所述出射光在450nm~700nm具有峰波长。
4.根据权利要求1~3中任一项所述的抗氧化剂或皮肤应激抑制剂,所述波长转换物质包含选自别藻蓝蛋白、C-藻蓝蛋白、R-藻蓝蛋白、藻红蓝蛋白、B-藻红蛋白、b-藻红蛋白、C-藻红蛋白、和R-藻红蛋白中的1种或多种藻胆蛋白;选自氧化锌荧光体、钛酸镁荧光体、和磷酸钙荧光体中的1种或多种无机荧光体;选自维生素A、β胡萝卜素、维生素K、维生素B1、维生素B2、维生素B6、维生素B12、叶酸、烟酸、番茄红素、栀子、红花、姜黄、胭脂虫红、紫苏、紫甘蓝、黄酮类、类胡萝卜素、醌型化合物、卟啉类、花色素苷类、和多酚类中的1种或多种成分;以及/或选自红色401号、红色227号、红色504号、红色218号、橙色205号P、黄色4号、黄色5号、绿色201号、绿色204号、蓝色1号、2,4-二氨基苯氧基乙醇盐酸盐、紫色201号、紫色401号、黑色401号、红色226号、黄色401号、黄色205号、蓝色404号、红色104号、和间氨基苯酚中的1种或多种色素。
5.根据权利要求4所述的抗氧化剂或皮肤应激抑制剂,所述波长转换物质包含选自别藻蓝蛋白、C-藻蓝蛋白、R-藻蓝蛋白、藻红蓝蛋白、B-藻红蛋白、b-藻红蛋白、C-藻红蛋白、和R-藻红蛋白中的1种或多种藻胆蛋白;选自氧化锌荧光体、钛酸镁荧光体、和磷酸钙荧光体中的1种或多种无机荧光体;以及/或选自维生素B1、维生素B2、维生素B6、和维生素B12中的1种或多种维生素B。
6.一种组合物,其含有权利要求1~5中任一项所述的抗氧化剂或皮肤应激抑制剂。
7.根据权利要求6所述的组合物,所述组合物为皮肤外用组合物,其用于通过使皮肤暴露于包含紫外线的光而在皮肤中的氧化和/或皮肤应激的抑制。
8.一种用于在对象的皮肤中抑制氧化和/或皮肤应激的美容方法,其包含:
将权利要求6或7所述的组合物涂抹于对象的皮肤;以及
使涂抹所述组合物后的皮肤暴露于包含紫外线的光。
9.一种制品,其含有权利要求1~5中任一项所述的抗氧化剂或皮肤应激抑制剂。
10.根据权利要求9所述的制品,所述制品用于通过使皮肤暴露于使包含紫外线的光通过了该制品后的光从而在皮肤中抑制氧化和/或皮肤应激。
11.一种用于在对象的皮肤中抑制氧化和/或皮肤应激的美容方法,其包含:
使包含紫外线的光通过权利要求9或10所述的制品;以及
使对象的皮肤暴露于所述通过光。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020015642 | 2020-01-31 | ||
JP2020-015642 | 2020-01-31 | ||
PCT/JP2021/003381 WO2021153780A1 (ja) | 2020-01-31 | 2021-01-29 | 抗酸化剤又は皮膚ストレス抑制剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115023216A true CN115023216A (zh) | 2022-09-06 |
Family
ID=77078904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180010516.2A Pending CN115023216A (zh) | 2020-01-31 | 2021-01-29 | 抗氧化剂或皮肤应激抑制剂 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20230050588A1 (zh) |
JP (1) | JPWO2021153780A1 (zh) |
CN (1) | CN115023216A (zh) |
WO (1) | WO2021153780A1 (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05117127A (ja) * | 1991-10-02 | 1993-05-14 | Shiseido Co Ltd | 蛍光化粧料 |
JP2017155062A (ja) * | 2017-06-15 | 2017-09-07 | 株式会社東洋新薬 | 美容組成物 |
KR20190005369A (ko) * | 2017-07-06 | 2019-01-16 | 한국 한의학 연구원 | 씨-피코시아닌을 유효성분으로 함유하는 피부 주름의 예방 또는 개선용 조성물 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000219607A (ja) * | 1999-01-28 | 2000-08-08 | Shiseido Co Ltd | 外用組成物 |
FR2995531B1 (fr) * | 2012-09-20 | 2014-10-10 | Ecosystem | Procede d'extraction et de stabilisation de phycocyanine et ses applications |
CN105055251B (zh) * | 2015-08-29 | 2018-06-15 | 云南蓝钻生物科技股份有限公司 | 一种抗衰老化妆品及其制备方法 |
US11312902B2 (en) * | 2016-06-30 | 2022-04-26 | Sakai Chemical Industry Co., Ltd. | Zinc oxide phosphor and method for producing same |
JP7234510B2 (ja) * | 2017-11-29 | 2023-03-08 | 堺化学工業株式会社 | 化粧料 |
-
2021
- 2021-01-29 CN CN202180010516.2A patent/CN115023216A/zh active Pending
- 2021-01-29 JP JP2021574722A patent/JPWO2021153780A1/ja active Pending
- 2021-01-29 US US17/796,584 patent/US20230050588A1/en active Pending
- 2021-01-29 WO PCT/JP2021/003381 patent/WO2021153780A1/ja active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05117127A (ja) * | 1991-10-02 | 1993-05-14 | Shiseido Co Ltd | 蛍光化粧料 |
JP2017155062A (ja) * | 2017-06-15 | 2017-09-07 | 株式会社東洋新薬 | 美容組成物 |
KR20190005369A (ko) * | 2017-07-06 | 2019-01-16 | 한국 한의학 연구원 | 씨-피코시아닌을 유효성분으로 함유하는 피부 주름의 예방 또는 개선용 조성물 |
Non-Patent Citations (1)
Title |
---|
堺化学工業株式会社: "光る新化粧品原料 無機蛍光粉末Lumateシリーズ", FRAGRANCE JOURNAL, vol. 43, no. 7, 15 July 2015 (2015-07-15), pages 62 - 63 * |
Also Published As
Publication number | Publication date |
---|---|
JPWO2021153780A1 (zh) | 2021-08-05 |
US20230050588A1 (en) | 2023-02-16 |
WO2021153780A1 (ja) | 2021-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020202764A1 (ja) | 細胞賦活剤 | |
Sen et al. | Mycosporine-like amino acids: Algal metabolites shaping the safety and sustainability profiles of commercial sunscreens | |
CN115023216A (zh) | 抗氧化剂或皮肤应激抑制剂 | |
WO2021153773A1 (ja) | 光老化抑制剤 | |
WO2021153776A1 (ja) | 血管新生抑制剤 | |
WO2020204193A1 (ja) | 紫外線波長変換物質を含有する組成物 | |
WO2002081027A1 (en) | An antioxidant composition and a cosmetic or pharmaceutical composition | |
CN115052579A (zh) | 透明质酸产生促进剂 | |
Sjerobabski Masnec et al. | New option in photoprotection | |
WO2021153788A1 (ja) | 皮膚バリア機能亢進剤 | |
WO2021153781A1 (ja) | コラーゲン糖化抑制剤 | |
CN115003269A (zh) | 胶原产生能力的维持或促进剂 | |
JP2024031635A (ja) | 可視光によりフラボノイドの生理作用を増強するための美容方法 | |
WO2021153783A1 (ja) | 炎症抑制剤 | |
JP2021172607A (ja) | 紫外線波長変換物質、炭化水素油及び/又は直鎖シリコーン油、並びに粉末を含有する肌用組成物 | |
CN113692288A (zh) | 含有紫外线波长转换物质的水包油型乳液组合物 | |
JP2024031642A (ja) | 可視光によりリボフラビンの生理作用を増強するための美容方法 | |
US20220160604A1 (en) | Emulsion composition comprising ultraviolet wavelength conversion substance and organic oily phase thickener | |
JP2021107369A (ja) | 紫外線波長変換物質を含有する組成物 | |
JP2021107367A (ja) | 紫外線波長変換物質を含有する水中油型乳化組成物 | |
JP2021107368A (ja) | 紫外線波長変換物質及び有機系油相増粘剤を含有する乳化組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |